Low dosage of a novel SARS-COV-2 mRNA-VLP vaccine elicits equivalent cell-mediated immunity to a licensed mRNA vaccine 2260043
The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)
DOI: 10.1093/jimmun/vkag141.839 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Michael Powell und 10 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction mRNA-encoded virus-like particles (VLPs) are an emerging advancement in vaccine technology, enabling the self-assembly of viral antigens into structures that closely resemble native viruses. This innovative approach to conventional mRNA vaccination may boost vaccine-induced adaptive immune responses and allow for reduced dosing. To evaluate this technology, we developed AZD6563, an mRNA VLP vaccine targeting the COVID-19 XBB1.5 spike variant.
Methods
The phase 1 clinical study ARTEMIS-C was conducted to assess cellular immunogenicity in adults aged 18—64 years and ≥65 years following administration of AZD6563 (5 µg or 10 µg) or the licensed BNT162b2 XBB.1.5 mRNA vaccine (30 µg).
Results
AZD6563 drove spike-specific CD4+ and CD8+ T cell responses comparable to those elicited by higher dose of BNT162b2. Functional analysis of these cells revealed similar cytokine production profiles across groups; however, the 10µg dose of AZD6563 led to higher TCR diversity within the ≥65-year cohort. Notably, expansion of spike-specific B cells was most pronounced in the AZD6563 10µg group, with marked increases in cross-reactive XBB.1.5 spike-specific B cells that also recognized Omicron BA.4/5 and ancestral SARS-CoV-2 variants.
Conclusion
Collectively, these results demonstrate that AZD6563, at reduced doses, matches the cellular immunogenicity of BNT162b2 while enhancing B cell cross-reactivity and TCR diversity in older adults, supporting its potential as a next-generation COVID-19 vaccine candidate. Funding Source n/a Topic Categories Vaccines and Immunotherapy (VAC)
Zitieren
APA
Powell, M., Battaglia, N., Chang, L., Cimbro, R., Berman, S. C., Oyedele, T., Pack, A., Padilla, M., Roe, T., Stanley, A. M., & Swanson, P. (2026). Low dosage of a novel SARS-COV-2 mRNA-VLP vaccine elicits equivalent cell-mediated immunity to a licensed mRNA vaccine 2260043. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.839
Vancouver
Powell M, Battaglia N, Chang L, Cimbro R, Berman SC, Oyedele T, et al. Low dosage of a novel SARS-COV-2 mRNA-VLP vaccine elicits equivalent cell-mediated immunity to a licensed mRNA vaccine 2260043. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.839
BibTeX
@article{Powell2026,
author = {Powell, Michael and Battaglia, Nicholas and Chang, Lee-Jah and Cimbro, Raffaeloo and Berman, Stacey Cromer and Oyedele, Tope and Pack, Angela and Padilla, Marcelino and Roe, Tiffany and Stanley, Ann Marie and Swanson, Phillip},
title = {Low dosage of a novel SARS-COV-2 mRNA-VLP vaccine elicits equivalent cell-mediated immunity to a licensed mRNA vaccine 2260043},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {Supplement_1},
doi = {10.1093/jimmun/vkag141.839}
}
EUVIMED